Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hzVSF-v13 in Moderate to Severe COVID-19
NCT04679415Phase 2Completed
- Sponsor
- ImmuneMed Inc.
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of burfiralimab in COVID-19 pneumonia (3 arms), sponsored by ImmuneMed Inc. Primary endpoint: Clinical failure rate at Day 28. Started Dec 2020; status: completed.
02
Drugs
burfiralimab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04679415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679415.